Halozyme Therapeutics
HALO
#2614
Rank
$4.90 B
Marketcap
$38.64
Share price
2.20%
Change (1 day)
13.98%
Change (1 year)

P/E ratio for Halozyme Therapeutics (HALO)

P/E ratio as of April 2024 (TTM): 21.7

According to Halozyme Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 21.7299. At the end of 2022 the company had a P/E ratio of 38.4.

P/E ratio history for Halozyme Therapeutics from 2004 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202238.4172.5%
202114.1-68.29%
202044.5-225.46%
2019-35.533.31%
2018-26.6-152.52%
201750.7-515.25%
2016-12.2-81.7%
2015-66.7279.89%
2014-17.5-14.56%
2013-20.549.95%
2012-13.7-71.2%
2011-47.6236.21%
2010-14.163.84%
2009-8.63-4.43%
2008-9.03-59.35%
2007-22.2-33.76%
2006-33.5360.74%
2005-7.28-13.96%
2004-8.46

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
10.3-52.38%๐Ÿ‡บ๐Ÿ‡ธ USA
13.7-37.18%๐Ÿ‡บ๐Ÿ‡ธ USA
137 532.28%๐Ÿ‡บ๐Ÿ‡ธ USA
14.3-34.32%๐Ÿ‡ซ๐Ÿ‡ท France
7.74-64.36%๐Ÿ‡บ๐Ÿ‡ธ USA
-21.5-198.82%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.